Defective insulin signaling and the protective effects of dimethyldiguanide during follicular development in the ovaries of polycystic ovary syndrome

Wang,Fan; Wang,Shaobing; Zhang,Zhenghong; Lin,Qingqiang; Liu,Yiping; Xiao,Yijun; Xiao,Kaizhuan; Wang,Zhengchao

doi:10.3892/mmr.2017.7678

Defective insulin signaling and the protective effects of dimethyldiguanide during follicular development in the ovaries of polycystic ovary syndrome

Authors:
- Fan Wang
- Shaobing Wang
- Zhenghong Zhang
- Qingqiang Lin
- Yiping Liu
- Yijun Xiao
- Kaizhuan Xiao
- Zhengchao Wang
View Affiliations

Affiliations: Provincial Key Laboratory for Developmental Biology and Neurosciences, College of Life Sciences, Fujian Normal University, Fuzhou, Fujian 350007, P.R. China, State Key Laboratory for Evaluation of Exercise Physiological Functions from General Administration of Sport of China, School of Physical Education and Sport Sciences, Fujian Normal University, Fuzhou, Fujian 350007, P.R. China
Published online on: September 29, 2017 https://doi.org/10.3892/mmr.2017.7678
Pages: 8164-8170
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It is established that the physiological effects of insulin are primarily mediated by the insulin signaling pathway. However, a defective insulin signaling is closely associated with the clinical manifestations of polycystic ovary syndrome (PCOS), which include excess androgen levels, insulin resistance and anovulation, and is involved in the pathophysiology of PCOS at the molecular level. Dimethyldiguanide (DMBG) has been widely employed to alleviate reproduction dysfunction in women with PCOS, however, the exact mechanism of this effect remains unclear. The objective of the present study was to investigate the effects of DMBG on the expression of the insulin signaling pathway in the ovaries of rats with PCOS, and to identify the potential underlying molecular mechanisms of these effects in PCOS. In the present study, a PCOS rat model was induced by letrozole, and successful establishment of the model was confirmed by examining ovarian histology and determining serum testosterone levels, by hematoxylin and eosin staining and ELISA, respectively. Subsequently, the expression of two key elements of insulin signaling, insulin receptor substrate (IRS)‑2 and phosphatidylinositol 3‑kinase (PI3K), was determined by immunohistochemistry and western blot analysis. The results demonstrated that IRS‑2 and PI3K expression was markedly decreased in PCOS ovaries, which was rescued by DMBG treatment. These results indicate that IRS‑2/PI3K signaling may be involved in the development of PCOS and the therapeutic effects of DMBG on PCOS. To further confirm the effects of DMBG on insulin signaling expression during this process, the expression of an additional two downstream proteins, phosphoinositide‑dependent kinase‑1 (PDK‑1) and the mammalian target of rapamycin (mTOR), was also investigated in the present study, and the results demonstrated that the expression of PDK‑1 and mTOR was significantly reduced in PCOS ovaries and increased following DMBG treatment, further indicating that altered insulin signaling may have an important role in the development and treatment of PCOS. In conclusion, the results of the present study indicate that the reduced expression of proteins involved in insulin signaling may contribute to the development of the clinical features of PCOS, and DMBG reverses reduced expression of insulin signaling components, by a mechanism that is yet to be determined, to attenuate certain symptoms of PCOS, such as obesity. To the best of our knowledge, the present study is the first to provide data regarding the detailed changes of insulin signaling during the development and treatment of PCOS, and may provide an important reference for clinical PCOS treatment.

View Figures

View References

1	Broekmans FJ and Fauser BC: Diagnostic criteria for polycystic ovarian syndrome. Endocrine. 30:3–11. 2006. View Article : Google Scholar : PubMed/NCBI
2	Lane DE: Polycystic ovary syndrome and its differential diagnosis. Obstet Gynecol Surv. 61:125–135. 2006. View Article : Google Scholar : PubMed/NCBI
3	Makker A, Goel MM, Das V and Agarwal A: PI3K-Akt-mTOR and MAPK signaling pathways in polycystic ovarian syndrome, uterine leiomyomas and endometriosis: An update. Gynecol Endocrinol. 28:175–181. 2012. View Article : Google Scholar : PubMed/NCBI
4	Zhao Y, Zhang C, Huang Y, Yu Y, Li R, Li M, Liu N, Liu P and Qiao J: Up-regulated expression of WNT5a increases inflammation and oxidative stress via PI3K/AKT/NF-κB signaling in the granulosa cells of PCOS patients. J Clin Endocrinol Metab. 100:201–211. 2015. View Article : Google Scholar : PubMed/NCBI
5	Li T, Mo H, Chen W, Li L, Xiao Y, Zhang J, Li X and Lu Y: Role of the PI3K-Akt signaling pathway in the pathogenesis of polycystic ovary syndrome. Reprod Sci. 24:646–655. 2017. View Article : Google Scholar : PubMed/NCBI
6	Azziz R: Polycystic ovary syndrome, insulin resistance and molecular defects of insulin signaling. J Clin Endocrinol Metab. 87:4085–4087. 2002. View Article : Google Scholar : PubMed/NCBI
7	Dunaif A: Insulin resistance in women with polycystic ovary syndrome. Fertil Steril. 86 Suppl 1:S13–S14. 2006. View Article : Google Scholar : PubMed/NCBI
8	Vollenweider P: Insulin resistant states and insulin signaling. Clin Chem Lab Med. 41:1107–1119. 2003. View Article : Google Scholar : PubMed/NCBI
9	Skrgatić L, Baldani DP, Gersak K, Cerne JZ, Ferk P and Corić M: Genetic polymorphisms of INS, INSR and IRS-1 genes are not associated with polycystic ovary syndrome in Croatian women. Coll Antropol. 37:141–146. 2013.
10	Ciaraldi TP: Molecular defects of insulin action in the polycystic ovary syndrome: Possible tissue specificity. J Pediatr Endocrinol Metab. 13 Suppl 5:S1291–S1293. 2000.
11	Diamanti-Kandarakis E, Argyrakopoulou G, Economou F, Kandaraki E and Koutsilieris M: Defects in insulin signaling pathways in ovarian steroidogenesis and other tissues in polycystic ovary syndrome (PCOS). J Steroid Biochem Mol Biol. 109:242–246. 2008. View Article : Google Scholar : PubMed/NCBI
12	Book CB and Dunaif A: Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 84:3110–3116. 1999. View Article : Google Scholar : PubMed/NCBI
13	Wu XK, Zhou SY, Liu JX, Pöllänen P, Sallinen K, Mäkinen M and Erkkola R: Selective ovary resistance to insulin signaling in women with polycystic ovary syndrome. Fertil Steril. 80:954–965. 2003. View Article : Google Scholar : PubMed/NCBI
14	Venkatesan AM, Dunaif A and Corbould A: Insulin resistance in polycystic ovary syndrome: Progress and paradoxes. Recent Prog Horm Res. 56:295–308. 2001. View Article : Google Scholar : PubMed/NCBI
15	Shah KN and Patel SS: Phosphatidylinositide-3 kinase: A newer molecular target in metabolic and hormonal pathway of polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 122:261–267. 2014. View Article : Google Scholar : PubMed/NCBI
16	Saltiel AR and Pessin JE: Insulin signaling pathways in time and space. Trends Cell Biol. 12:65–71. 2002. View Article : Google Scholar : PubMed/NCBI
17	Tan MH, Alquraini H, Mizokami-Stout K and MacEachern M: Metformin: From research to clinical practice. Endocrinol Metab Clin North Am. 45:819–843. 2016. View Article : Google Scholar : PubMed/NCBI
18	Genazzani AD, Ricchieri F and Lanzoni C: Use of metformin in the treatment of polycystic ovary syndrome. Womens Health (Lond). 6:577–593. 2010. View Article : Google Scholar : PubMed/NCBI
19	Fruzzetti F, Perini D, Russo M, Bucci F and Gadducci A: Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). Gynecol Endocrinol. 33:39–42. 2017. View Article : Google Scholar : PubMed/NCBI
20	Tan X, Li S, Chang Y, Fang C, Liu H, Zhang X and Wang Y: Effect of metformin treatment during pregnancy on women with PCOS: A systematic review and meta-analysis. Clin Invest Med. 39:E120–E131. 2016. View Article : Google Scholar : PubMed/NCBI
21	Genazzani AD, Strucchi C, Luisi M, Casarosa E, Lanzoni C, Baraldi E, Ricchieri F, Mehmeti H and Genazzani AR: Metformin administration modulates neurosteroids secretion in non-obese amenorrhoic patients with polycystic ovary syndrome. Gynecol Endocrinol. 22:36–43. 2006. View Article : Google Scholar : PubMed/NCBI
22	Genazzani AD, Lanzoni C, Ricchieri F, Baraldi E, Casarosa E and Jasonni VM: Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia. Gynecol Endocrinol. 23:146–152. 2007. View Article : Google Scholar : PubMed/NCBI
23	Wang F, Zhang Z and Wang Z, Xiao K, Wang Q, Su J and Wang Z: Expression and clinical significance of the HIF-1a/ET-2 signaling pathway during the development and treatment of polycystic ovary syndrome. J Mol Histol. 46:173–181. 2015. View Article : Google Scholar : PubMed/NCBI
24	Palomba S, Falbo A, Zullo F and Orio F Jr: Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: A comprehensive review. Endocr Rev. 30:1–50. 2009. View Article : Google Scholar : PubMed/NCBI
25	Li X, Guo YR, Lin JF, Feng Y, Billig H and Shao RJ: Combination of diane-35 and metformin to treat early endometrial carcinoma in PCOS women with insulin resistance. J Cancer. 5:173–181. 2014. View Article : Google Scholar : PubMed/NCBI
26	White MF: The IRS-signaling system: A network of docking proteins that mediate insulin and cytokine action. Recent Prog Horm Res. 53:119–138. 1998.PubMed/NCBI
27	Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S, Zhang Y, Bernal D, Pons S, Shulman GI, et al: Disruption of IRS-2 causes type 2 diabetes in mice. Nature. 391:900–904. 1998. View Article : Google Scholar : PubMed/NCBI
28	Kubota N, Tobe K, Terauchi Y, Eto K, Yamauchi T, Suzuki R, Tsubamoto Y, Komeda K, Nakano R, Miki H, et al: Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. Diabetes. 49:1880–1889. 2000. View Article : Google Scholar : PubMed/NCBI
29	Burks DJ, de Mora J Font, Schubert M, Withers DJ, Myers MG, Towery HH, Altamuro SL, Flint CL and White MF: IRS-2 pathways integrate female reproduction and energy homeostasis. Nature. 407:377–382. 2000. View Article : Google Scholar : PubMed/NCBI
30	Mlinar B, Marc J, Janez A and Pfeifer M: Molecular mechanisms of insulin resistance and associated diseases. Clin Chim Acta. 375:20–35. 2007. View Article : Google Scholar : PubMed/NCBI
31	Shepherd PR, Withers DJ and Siddle K: Phosphoinositide 3-kinase: The key switch mechanism in insulin signalling. Biochem J. 333:471–490. 1998. View Article : Google Scholar : PubMed/NCBI
32	Wang LH, Wang X, Yu XZ and Xu WT: Potent therapeutic effects of shouwu jiangqi decoction on polycystic ovary syndrome with insulin resistance in rats. Chin J Integr Med. 22:116–123. 2016. View Article : Google Scholar : PubMed/NCBI
33	Gagliardi PA, di Blasio L and Primo L: PDK1: A signaling hub for cell migration and tumor invasion. Biochim Biophys Acta. 1856:178–188. 2015.PubMed/NCBI
34	Li Y, Yang KJ and Park J: Multiple implications of 3-phosphoinositide-dependent protein kinase 1 in human cancer. World J Biol Chem. 1:239–247. 2010. View Article : Google Scholar : PubMed/NCBI
35	Siddappa D, Kalaiselvanraja A, Bordignon V, Dupuis L, Gasperin BG, Roux PP and Duggavathi R: Mechanistic target of rapamycin (MTOR) signaling during ovulation in mice. Mol Reprod Dev. 81:655–665. 2014. View Article : Google Scholar : PubMed/NCBI